Quantitative proteomics is increasingly being applied to examine and understand how cells and organisms regulate their metabolism in order to support growth, proliferation, differentiation, development and survival.[@R1] Several different strategies for quantitative proteomics have been developed including label-free quantification, chemical labeling e.g., iTRAQ and dimethyl labeling or metabolic labeling using heavy isotopes.[@R2]^-^[@R5] The simplest strategy is label-free quantification, where signal intensities of a given peptide in a number of spectra are used as an estimate of the abundance of the sample protein.[@R3] Such an approach does not require any sample preparation prior to analysis, thus this approach is applicable to all kinds of samples and an indefinite number of experiments can be compared. However, this methodology suffers from sensitivity to variations in sample composition that can easily affect ionization of the relevant peptide and hence alter its apparent abundance. Consequently, as sample complexity grows the utility of such strategy declines. Instead, several labeling approaches have been developed that benefit from stable isotopes having the same physicochemical properties except from their masses, making distinguishable by mass spectrometry. In vitro labeling includes incorporation of ^18^O by enzymatic hydrolysis in heavy water and chemical labeling of amino acids containing certain reactive groups.[@R3] The latter features isotope-coded affinity tags to facilitate purification and isobaric tags for relative and absolute quantitation (iTRAQ). iTRAQ are isobaric tags that, upon fragmentation, release reporter ions of unique masses. The advantage of these in vitro approaches is that any sample or tissue can be labeled. However, the samples undergo a number of preparation steps before labeling and mixing, which increases the risk of introducing a quantitative bias in the samples and thereby decreasing the quantitative accuracy.

Particularly, metabolic labeling with stable isotopes has become the prevailing strategy to quantitatively compare proteomes of cells and organisms. *C. elegans* has during the past decade proven to be a powerful model in identification and characterization of novel genes and signaling pathways regulating cell division, development, aging, apoptosis and metabolism.[@R1] However, quantitative proteomics has only to a limited extent been applied to study signaling events governing metabolism in *C. elegans*. In 2003 Krijgsveld et al. showed that *C. elegans* animals can be metabolically labeled with ^15^N by feeding them on ^15^N-labeled *E. coli* for two generations,[@R6] that, when combined with an ^14^N-labeled worm population, could be used to determine the relative protein abundance among the two populations by mass spectrometry. Henceforth, they applied this strategy to identify differentially expressed proteins in *glp-4* animals compared with wild type animals.[@R6] Analogously, Yates and coworkers examined how loss of functional insulin receptors affects the proteome of *C. elegans*, and identified novel key regulators of insulin regulated metabolic outputs.[@R7] Recently, Simonsen et al. used a similar approach to identify differentially expressed proteins in *C. elegans* in response to short- and long-term infection by a pathogenic adherent-invasive strain of *E. coli*, that were isolated from patients suffering from the inflammatory bowel disease Crohn disease.[@R8] However, compared with metabolic labeling with ^15^N, stable isotope labeling by amino acids in cell culture[@R9]^,^[@R10] (SILAC) provides a more precise mass spectrometry-based quantitative strategy, as it provides a defined number of labels per identified peptide and therefore enables easier and more comprehensive peptide identification and data analysis. Such methodologies have proven to be a highly valuable tool for studies in in vivo systems like the yeast *Saccharomyces cerevisiae*,[@R9]^,^[@R11] the fruit fly *Drosophila melanogaster*,[@R12] the plant *Arabidopsis thaliana*[@R13] and mice.[@R14] Recently, our laboratory and others added *C. elegans* to the SILAC zoo (see below).[@R15]^,^[@R16]

We have shown that *C. elegans* can be completely labeled by stable isotope labeled lysine by feeding animals on a lysine auxotroph *E. coli* strain for a single generation.[@R15] Moreover, following protein extraction from light and heavy labeled *C. elegans* we showed that peptides can be identified and quantified with high accuracy (standard deviation of log~2~ = 0.22), which is comparable to similar approaches applied on the fruit fly *Drosophila melanogaster*.[@R12] SILAC based quantitative proteomics is typically based on labeling with both arginine and lysine, which provides one label per peptide after trypsin digestion, and hence improved proteome coverage. Although we only labeled *C. elegans* with lysine, and subsequently digested with lysyl endopeptidase (Lys-C) resulting in longer peptides, we were able to identify and quantify a vast number of proteins due to intensive peptide fractionation prior to mass spectrometry analysis. Moreover, arginine to proline conversion imposes a major challenge in peptide identification and quantification. To this end, Larance et al. recently showed that up to 20% of the proline become labeled when *C. elegans* is labeled with arginine, which can be prevented by RNAi mediated knock down of ornithine transaminase, *orn-1*, required for the conversion.[@R16] However, labeling with lysine combined with extensive peptide fractionation may be advantageous as *orn-1* knock down may interfere with the metabolism of the nematode, and prevents that other genes are efficiently knocked down by RNAi.[@R17]

One of the major advantages by *C. elegans* as a model organism is the unprecedented applicability of RNA interference to systematically study gene functions. We therefore rendered the lysine auxotroph *E. coli* strain RNAi compatible by modifying it to express the T7 RNA polymerase from an IPTG-inducible promoter and by eliminating RNaseIII to prevent degradation of dsRNA in *E. coli*. Subsequently, to validate the use of lysine labeling of *C. elegans* in quantitative proteomics studies we aimed to identify differentially expressed proteins in response to functional loss or RNAi mediated knock down of the nuclear hormone receptor NHR-49. The expression of genes involved in lipid metabolism in *C. elegans* is coordinately controlled by a number of transcription factors including the NHR-49, which is a hepatocyte nuclear factor (HNF)-4α ortholog and has a function analogous to that of peroxisome proliferator-activated receptor α, PPARα, in mammals. By quantitative proteomics we identified 3949 and 4627 proteins, respectively, of which 143 and 330 proteins were differentially expressed in response to disruption or knock down of NHR-49 function.[@R15] Among the downregulated proteins we identified proteins involved in lipid metabolism to be significantly overrepresented. In particular, we found that the Δ9 fatty acid desaturases FAT-5 and FAT-6, which previously have been shown to be controlled by NHR-49,[@R18] were significantly downregulated in response to functional loss or knockdown of *nhr-49*. Moreover, we found FAT-1 and FAT-2, an ω3 fatty acid desaturase and a Δ12 fatty acid desaturase, respectively, to be downregulated. This observation supports the notion that loss of NHR-49 function impedes on fatty acid desaturation leading to accumulation of saturated fatty acids.[@R18] Besides *fat-5, fat-6* and *fat-7*, van Gilst et al. also found three genes involved in mitochondrial β-oxidation of fatty acids (*ech-1*, *cpt-5* and *acs-2*), three genes involved in peroxisomal β-oxidation (two putative acyl-CoA oxidases and *ech-9*), two genes involved in fatty acid binding/transport (*lbp-7* and *lbp-8*) and two genes involved in the glyoxylate pathway (*gei-7* and *sdha-1*), arguing that NHR-49 is required for fatty acid degradation in *C. elegans*.[@R18] Accordingly, *nhr-49* animals have enlarged lipid stores.[@R18] Consistently, we find an array of proteins ([Fig. 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) to be downregulated in *nhr-49* animals that either have been shown, or based on sequence similarities to functionally characterized gene products from other model organisms like *Saccharomyces cerevisiae* and mice, are predicted to be involved in β-oxidation of fatty acids or metabolism of acetyl-CoA. Since these proteins contain a C-terminal peroxisomal targeting signal or that their mammalian counterpart previously has been identified to the peroxisomes, our observations suggest that NHR-49 primarily regulates peroxisomal β-oxidation rather than mitochondrial β-oxidation, as suggested by van Gilst et al.[@R18] The inability to degrade long-chain fatty acids would consequently result in increased intracellular levels of unbound fatty acids and fatty acyl-CoA esters. Consistent with this notion, we find the predicted fatty acid binding protein LBP-3 and acyl-CoA binding protein ACBP-1 to be upregulated in response to loss of NHR-49 function. These binding proteins may bind, sequester and hence protect cells from detrimental effects of large increases in free fatty acid and acyl-CoA levels, respectively. The fact that we also find glutathione and xenobiotic metabolism to be upregulated may also reflect an increased cellular stress response in response to loss of NHR-49 function.

![**Figure 1.** Downregulation of *nhr-49* by RNAi affects the abundance of proteins involved in fatty acid metabolism. Stable amino acid labeling and quantitative proteomics was use to identify the differentially expressed proteins in L4 stage nematodes treated with *nhr-49* RNAi compared with empty vector controls. Among the regulated proteins, enzymes involved in fatty acid metabolism, especially peroxisomal β-oxidation, are significantly overrepresented. The indicated protein is known or predicted, based on sequence homology to yeast or mouse orthologs, to be involved in the indicated biochemical pathway. Green and red indicate proteins that become less and more abundant, respectively, in response to RNAi mediated knock down of *nhr-49*.](worm-1-66-g1){#F1}

###### **Table 1.** NHR-49 affects abundance of metabolic enzymes. Quantitative proteomics was use to identify the differentially expressed proteins in L4 stage nematodes treated with nhr-49 RNAi compared to empty vector controls. Among the total number of identified regulated proteins a subset is shown. The log~2~ ratios indicate less or more abundant proteins after RNAi against NHR-49. See Fredens et al. for details.[@R15]

  Biochemical Process                      Worm Protein   Log~2~   Function                                              Yeast homolog   Mouse homolog
  ---------------------------------------- -------------- -------- ----------------------------------------------------- --------------- ---------------
  **Amino acid metabolism**                K10H10.2       -1,28    Cysteine synthase                                     YGR012W         CBS
                                           F26H9.5        -0,59    Phosphoserine aminotransferase                        SER1            PSAT1
                                           C31C9.2        -0,35    3-phosphoglycerate dehydrogenase                      SER33           3-PGDH
                                           R102.4         0,35     Threonine aldolase                                    GLY1            THA1
                                           M02D8.4        -0,91    Asparagine synthetase                                 ASN2            ASNS
                                           Y51H4A.7       -0,62    Urocanate hydratase                                                   UROC1
                                           CTH-1          -1,37    Cystathionine gamma-lyase                             CYS3            CTH
                                           CTH-2          -0,69    Cystathionine gamma-lyase                             CYS3            CTH
                                           R12C12.1       0,19     Glycine decarboxylase                                 GCV2            GLDC
                                           DDO-2          -0,89    D-aspartate oxidase                                                   DDO
  **Carbohydrate metabolism**              W02H5.8        -0,52    Dihydroxyacetone kinase                               DAK1            DAK
                                           F53B1.4        0,35     UDP-glucose-4-epimerase                               GAL10           TGDS
                                           R11A5.4        -0,34    Phosphoenolpyruvat carboxykinase                                      PEPCK1
                                           FBP-1          -0,34    Fructose 1,6-bisphosphatase                           FBP1            FBP2
  **Mitochondrial energy metabolism**      ANT-1.2        -0,70    ADP/ATP translocator                                  AAC1            SLC25A31
                                           C44B7.10       -0,35    Acetyl-CoA hydrolase                                  ACH1             
                                           MAI-2          -0,41    ATPase inhibitor                                                      ATPIF1
                                           SUR-5          0,47     Acetoacetyl-CoA synthetase                            ACS2            AACS1
                                           W10C8.5        -0,44    Creatine kinase                                                       CKM
                                           ZC434.8        -0,41    Creatine kinase                                                       CKM
  **FA transport**                         ACS-22         -0,46    Fatty acid transport protein (FATP)                   FAT1            SLC27A4
                                           ACBP-1         0,27     Acyl-CoA-binding protein                              ACB1            L-ACBP
                                           LBP-3          0,45     Fatty acid binding protein (FABP)                                     FABP4
  **FA desaturation**                      FAT-1          -0,51    ω3-desaturase                                                          
                                           FAT-2          -0,50    Δ12-desaturase                                                         
                                           FAT-5          -2,31    Δ-9 desaturase                                        OLE1            SCD1
                                           FAT-6          -1,31    Δ-9 desaturase                                        OLE1            SCD1
  **Mitochondrial FA metabolism**          T20B3.1        -1,33    Carnitine O-acyltransferase                           CAT2            CROT
                                           ACS-2          -1,17    Acyl-CoA synthetase                                   FAA2            ACSF2
                                           MCE-1          -0,44    Methylmalonyl CoA epimerase                                           MCEE
                                           PYC-1          -0,52    Pyruvate carboxylase                                  PYC1            PCX
                                           D1005.1        0,31     ATP-citrate synthase: succinyl-CoA to succinate       LSC1            ACLY
                                           GEI-7          -0,84    Malate synthase                                       MLS1             
                                           ECH-4          -0,40    Enoyl-CoA hydratase/Acyl-CoA binding protein          ECI1            ECI2
                                           K09H11.1       -0,93    Acyl-CoA dehydrogenase                                                ACAD12
                                           ECH-7          0,28     Enoyl CoA hydratase                                   EHD3            ECHS1
  **Peroxisomal FA metabolism**            T20B3.1        -1,33    Carnitine O-acyltransferase                           CAT2            CROT
                                           ACS-1          -0,69    Acyl-CoA synthetase                                   FAT2            ACSF2
                                           ACS-7          -0,89    Acyl-CoA synthetase                                   FAT2            ACSF2
                                           ZK550.6        -1,49    Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA                      PHYH
                                           B0334.3        -0,78    2-hydroxyacyl-CoA lyase                               YEL020C         HACL1
                                           B0272.4        -1,18    Enoyl-CoA hydratase/isomerase                         ECI1            PECI
                                           F53C11.3       -0,69    2,4-dienoyl-CoA reductase                             SPS19           DECR1
                                           ACOX-1         -1,06    Acyl-CoA oxidase                                      POX1            ACOX1
                                           F08A8.2        -0,86    Acyl-CoA oxidase                                      POX1            ACOX1
                                           F58F9.7        -1,30    Acyl-CoA oxidase                                      POX1            ACOXL
                                           MAOC-1         -1,49    Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase   FOX2            MFE2
                                           DHS-18         -1,97    Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase   FOX2            HSDL2
                                           DHS-28         -0,62    Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase   FOX2            HSD17B4
                                           DAF-22         -1,25    Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase   FOX2            SCP2
                                           F53A2.7        -0,39    Acetyl-CoA acyltransferase                            ERG10           ACAA2
  **Lipid synthesis**                      Y71H10A.2      0,36     Fatty acyl CoA reductase                                              FAR1
                                           MBOA-3         0,52     Lysophospholipid acyltransferase                      ALE1            MBOAT1
                                           SPTL-1         0,26     Serine palmitoyltransferase                           LCB1            SPTLC1
                                           SPTL-2         0,49     Serine palmitoyltransferase                           LCB2            SPTLC3
                                           TAG-38         3,45     Sphingosine phosphate lyase                           DPL1            SGPL1
                                           PMT-1          -0,52    Phosphoethanolamine N-methyltransferase                                
                                           PMT-2          -0,45    Phosphoethanolamine N-methyltransferase               ISE1             
                                           R06C1.2        0,32     Farnesyl diphosphate synthetase                       ERG20           FDPS
  **Cholesterol transport**                VIT-6          -2,38    Cholesterol transport                                                  
                                           VIT-2          -2,09    Cholesterol transport                                                  
                                           VIT-4          -1,36    Cholesterol transport                                                  
  **Other groups**, dehydrogenases         F54F3.4        -1,24    short-chain dehydrogenases/reductases family          SPS19           DHRS4
                                           DHS-9          -0,72    short-chain dehydrogenases/reductases family          YMR226C         DHRS1
                                           DHS-15         0,38     short-chain dehydrogenases/reductases family          YMR226C         DHRS4
                                           DHS-20         -0,96    Mitochondrial short-chain dehydrogenase               YMR226C         HSD16B6
                                           DHS-22         0,30     Mitochondrial short-chain dehydrogenase               ENV9            RDH12
  Cytochrome P450                          CYP-25A2       -1,02    Cytochrome P450                                       ERG11           CYP3A11
                                           CYP-29A2       -0,63    Cytochrome P450                                       ERG11           CT033759.1
                                           CYP-33A1       0,48     Cytochrome P450                                       ERG5            CYP17A1
                                           CYP-35C1       0,54     Cytochrome P450                                       ERG11           CYP17A1
                                           CYP-33C7       0,73     Cytochrome P450                                       ERG5            CYP17A1
                                           CYP-13A5       0,99     Cytochrome P450                                       DIT2            CYP46A1
                                           CYP-13A4       1,72     Cytochrome P450                                       DIT2            CYP46A1
  Proteases                                F21F8.4        -0,53    Vacuolar aspartyl protease (proteinase A)             PEP4            BACE2
                                           Y16B4A.2       0,24     Putative serine type carboxypeptidase                 YBR139W         CPVL
                                           Y40D12A.2      0,32     Putative serine type carboxypeptidase                 YBR139W         CTSA
                                           ASP-2          0,33     Vacuolar aspartyl protease (proteinase A)             PEP4            BACE2
                                           ASP-1          0,34     Vacuolar aspartyl protease (proteinase A)             PEP4            BACE2
                                           K12H4.7        0,35     Serine protease                                                       PRCP
                                           ASP-3          0,40     Vacuolar aspartyl protease (proteinase A)             PEP4            CTSD
                                           ASP-6          0,41     Vacuolar aspartyl protease (proteinase A)             PEP4            CTSD
                                           F13D12.6       0,43     Putative serine type carboxypeptidase                 YBR139W         CTSA
                                           C15C8.3        1,18     Vacuolar aspartyl protease (proteinase A)             PEP4            BACE2
                                           K10B2.2        1,27     Putative serine type carboxypeptidase                 YBR139W         CTSA
                                           Lon protease   -0,60    Serine protease                                       PIM1            LONP2
  ATP-binding cassette (ABC) transporter   HAF-4          0,23     ATP-binding cassette transporter                      MDL1            TAP2
                                           ABT-4          0,36     ATP-binding cassette transporter                      YOL075C         EP300
                                           MRP-2          0,38     ATP-binding cassette transporter                      YCF1            ABCC1
                                           PGP-6          0,56     ATP-binding cassette transporter                      STE6            ABCB11
                                           MRP-5          0,59     ATP-binding cassette transporter                      YOR1            ABCC12
                                           PGP-9          0,82     ATP-binding cassette transporter                      STE6            ABCB11
  Glutathione S-transferase                GST-6          0,73     Glutathione S-transferase                                             HPGDS
                                           GST-7          0,38     Glutathione S-transferase                                             HPGDS
                                           GST-38         1,01     Glutathione-S-transferase                                             HPGDS

Gene expression levels are often interpreted based on mRNA levels, yet, it is increasingly recognized that the mRNA and protein levels may not correlate.[@R19]^,^[@R20] While the abundance of the majority of the proteins, we identified to be regulated upon impaired NHR-49 function, correlated well with the mRNA levels previously reported by van Gilst et al.,[@R18] the level of some proteins did not correlate with the mRNA level.[@R15] This may be due to alternative RNA splicing, differences in the half-lives of mRNAs and proteins, as well as rates of transcription and translation.[@R21]

Conclusion
==========

Stable isotope labeling of *C. elegans* with lysine and/or arginine provides a simple and straightforward approach for in vivo incorporation of a label into proteins for mass spectrometry-based quantitative proteomics. We anticipate that the recently described labeling methodologies[@R15]^,^[@R16] greatly will facilitate characterization of gene functions in the multicellular organism *C. elegans* and become a widely used technique in all areas of *C. elegans* biology. In contrast to metabolic labeling with ^15^N, stable isotope labeling with amino acids provides an in vivo strategy to label proteins with different stable isotopic forms of the amino acids (e.g., lys0, lys4, lys8, Arg4 or Arg10), making it possible to monitor differences at the protein level between multiple conditions or over time in a quantitative manner. Thus, stable isotope labeling with amino acids can be used to monitor how genetic, chemical or environmental perturbations affect the proteome of *C. elegans* over time. Combined with enrichment of posttranslational modified peptides, e.g., phosphopeptides, this approach can also delineate how various signaling cascades are affected in response to a specific perturbation.
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